Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Apollo Hospitals: No clear signs - Views on News from Equitymaster
  • E-MAIL
  • A  A  A
  • Feb 21, 2003

    Apollo Hospitals: No clear signs

    Apollo Hospitals Enterprises Limited (AHEL), the largest hospital chain in the country has announced encouraging December quarter results. The company has reported a robust 24% topline growth in 3QFY03 while the bottomline growth has been limited to 11%. Bottomline growth has been aided by an improvement in margins.

    (Rs m) 3QFY02 3QFY03 Change
    Net Sales 893 1,105 23.7%
    Other Income 11 8 -27.3%
    Expenditure 717 881 22.9%
    Operating Profit (EBDIT) 176 224 27.3%
    Operating Profit Margin (%) 19.7% 20.3%  
    Interest 48 79 64.6%
    Depreciation 43 59 37.2%
    Profit before Tax 96 94 -2.1%
    Extraordinary items - -  
    Tax 44 36 -18.2%
    Profit after Tax/(Loss) 52 58 11.5%
    Net profit margin (%) 5.8% 5.2%  
    No. of Shares 39.5 39.5  
    Diluted Earnings per share* 5.3 5.9  
    P/E Ratio   16.0  
    (* annualised)      

    Topline growth has been mainly due to addition of new beds in the last one year. In the past year the company has added a total of 450 beds to 'owned' beds capacity. What is noticeable though is the fact that unlike September quarter where the operating margins actually dipped, they have shown signs of improvement in the December quarter. Consequently operating profits have seen a 27% YoY growth in the December quarter. This may be in part due to better utilisation of the new capacity. Fixed costs are now better spread due to higher utilisation. The rise in margins is despite the fact that low margin retail 'pharmacy' business is a major component of its operations now. Operating margins are likely to improve as the additional capacity gets absorbed and the utilisation increases.

    Despite the improvement in operating margins, bottomline growth has been restricted due considerable increase in interest and depreciation expenses. Due to this the profit before tax has been severely impacted to the extent that it has shown a contraction in 3QFY03 compared to the same period last year. Rise in these expenses indicates that the company is still absorbing the effect of addition of the 450 beds. Also, Apollo Hospitals has been borrowing for starting up joint ventures with others in India ( Apollo Gleneagles, Calcutta) and abroad (Apollo, Sri Lanka) and this has led to an increase in the debt levels and a consequent rise in the company's interest outgo.

    The company has however stated that it does not have any plans to add new capacity on its own and instead, plans to concentrate on increasing the hospitals under management. AHEL plans to increase the ratio between managed beds and owned beds from the current ratio of 1:1 to 1.5:1. At present nearly 80% of the total capital employed is towards the hospital division, which includes the pharmacy division.

    At Rs 99 the stock is trading at a P/E of 16x its annualised 3QFY03 earnings. The company has been exhibiting a volatile trend as far as financial performance is concerned. The company's performance in 1QFY03 was encouraging but its performance in 2QYF03 has been disappointing. While operating margins have shown improvement in the December quarter, other concerns are likely to plague the stock going forward.

    AHEL's initiatives to expand in the domestic as well as international markets have strained its finances leading to higher debt burden. This is apparent in the considerable increase of the company's interest expenses. Going forward earnings are likely to be subdued due to this. AHEL's focus on managed beds is a step in the right direction but it will be a while before revenues from this stream actually contribute significantly to the bottomline. The stock is likely to remain range bound until the clear benefits emerge from its new initiatives.



    Equitymaster requests your view! Post a comment on "Apollo Hospitals: No clear signs". Click here!


    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

    May 30, 2017

    US markets decline while other geographies grow in the quarter.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    Proxy Plays: A Smart Way to Bet on 'Off Limits' Companies(The 5 Minute Wrapup)

    Aug 4, 2017

    The small-cap space is full of small players that are clear proxies to great growth stories and Indian megatrends.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms


    Aug 17, 2017 (Close)


    • Track your investment in APOLLO HOSPITALS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks



    Compare Company With Charts